Compounds > ly 188544
Page last updated: 2024-12-07

ly 188544

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

LY 188544: RN given refers to cpd without isomeric designation; LY 188545 is the (S)-isomer; LY 188546 is the (R)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID126157
CHEMBL ID277208
CHEBI ID109336
SCHEMBL ID4285282
MeSH IDM0154473

Synonyms (28)

Synonym
AF-962/00505062
4-amino-n-(1-phenylethyl)benzamide
MLS000676087
smr000296394
benzamide, 4-amino-n-(1-phenylethyl)-
(+-)-4-amino-n-(1-phenylethyl)benzamide
ly 188544
brn 5338072
benzamide, 4-amino-n-(1-phenylethyl)-, (+-)-
85592-75-2
97042-55-2
CHEBI:109336
CHEMBL277208
AKOS000144267
NCGC00245695-01
HMS2721E23
STK734448
AKOS017258678
SCHEMBL4285282
LRMURALCBANCSV-UHFFFAOYSA-N
4-amino-n-(alpha-methylbenzyl)-benzamide
Q27188423
mfcd01666807
SR-01000296528-1
sr-01000296528
DTXSID90914203
LS-08629
CS-0313406
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzamides
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency11.22020.01846.806014.1254AID624417
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
Glycoprotein hormones alpha chainHomo sapiens (human)Potency1.58494.46688.344810.0000AID624291
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell population proliferationGlycoprotein hormones alpha chainHomo sapiens (human)
hormone-mediated signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
regulation of signaling receptor activityGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of steroid biosynthetic processGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell migrationGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid gland developmentGlycoprotein hormones alpha chainHomo sapiens (human)
luteinizing hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlycoprotein hormones alpha chainHomo sapiens (human)
negative regulation of organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid hormone generationGlycoprotein hormones alpha chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
protein bindingGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
extracellular regionGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
Golgi lumenGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone complexGlycoprotein hormones alpha chainHomo sapiens (human)
pituitary gonadotropin complexGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (40)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID126096Anticonvulsant activity against scMet (subcutaneous metrazole) induced seizure in mice at 30 min; +++ indicates activity at 100 mg/kg.1984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
Anticonvulsant activity of some 4-aminobenzamides.
AID226533Protective index measured as the ratio between TD50 and ED501986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Anticonvulsant activity of 2- and 3-aminobenzanilides.
AID129636Compound was evaluated for anticonvulsant activity against subcutaneous pentylenetetrazole-induced convulsions1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
Synthesis and anticonvulsant activity of analogues of 4-amino-N-(1-phenylethyl)benzamide.
AID226932Protective index is the ratio of TD50 to ED501987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
Synthesis and anticonvulsant activity of analogues of 4-amino-N-(1-phenylethyl)benzamide.
AID603228Inhibition of human recombinant PRMT1-mediated arginine methylation at 50 uM using nonhistone protein Npl3 substrate by ELISA2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
Acyl derivatives of p-aminosulfonamides and dapsone as new inhibitors of the arginine methyltransferase hPRMT1.
AID131994Hypnotic dose was evaluated in mice1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
Synthesis and anticonvulsant activity of analogues of 4-amino-N-(1-phenylethyl)benzamide.
AID132428Evaluation of inhibitory activity against scMet induced convulsions in mice1984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
Anticonvulsant activity of some 4-aminobenzamides.
AID132425Evaluation of inhibitory activity aagainst MES induced convulsions in mice. 1984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
Anticonvulsant activity of some 4-aminobenzamides.
AID126080Anticonvulsant activity against MES (maximal electroshock) induced seizure in mice at 4 hr; +++ indicates activity at 100 mg/kg.1984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
Anticonvulsant activity of some 4-aminobenzamides.
AID113998Effective dose evaluated against maximal electric seizures (MES) or convulsions in mice; activity value ranges from 13.41-21.431985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Anticonvulsant activity of some 4-aminobenzanilides.
AID140168Evaluated for toxicity by using rotarod test at in mice 30 min; ++ indicates activity at 300 mg/kg.1984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
Anticonvulsant activity of some 4-aminobenzamides.
AID122026Toxic dose was determined by the rotarod test in mice activity value ranges from 153.02-189.961985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Anticonvulsant activity of some 4-aminobenzanilides.
AID114485Compound for anticonvulsant activity against subcutaneous pentylenetetrazole-induced convulsions in mice after administration1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Anticonvulsant activity of 2- and 3-aminobenzanilides.
AID134727Lethal dose was evaluated in mice1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
Synthesis and anticonvulsant activity of analogues of 4-amino-N-(1-phenylethyl)benzamide.
AID226518Protective index (PI) which is defined as the ratio of TD50 to the ED50 (ScMet).1984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
Anticonvulsant activity of some 4-aminobenzamides.
AID126104Anticonvulsant activity against scMet (subcutaneous metrazole) induced seizure in mice at 4 hr; ++ indicates activity at 300 mg/kg.1984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
Anticonvulsant activity of some 4-aminobenzamides.
AID226534Protective index as the ratio of TD50 value against MES to that of ED50 value against MES.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Anticonvulsant activity of some 4-aminobenzanilides.
AID121848Compound for toxicity by rotarod assay method in mice after administration1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Anticonvulsant activity of 2- and 3-aminobenzanilides.
AID226517Protective index (PI) which is defined as the ratio of TD50 to the ED50 (MES).1984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
Anticonvulsant activity of some 4-aminobenzamides.
AID114486Compound for toxicity by rotarod assay method in mice after administration1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Anticonvulsant activity of 2- and 3-aminobenzanilides.
AID136094Compound was evaluated for anticonvulsant activity by rotarod procedures1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
Synthesis and anticonvulsant activity of analogues of 4-amino-N-(1-phenylethyl)benzamide.
AID126075Anticonvulsant activity against MES (maximal electroshock) induced seizure in mice at 30 min; ++++ indicates activity at 30 mg/kg.1984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
Anticonvulsant activity of some 4-aminobenzamides.
AID226535Protective index as the ratio of TD50 value against scMET to that of ED50 value against scMET.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Anticonvulsant activity of some 4-aminobenzanilides.
AID136106Evaluation of neurologic deficit by rotarod procedure in mice1984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
Anticonvulsant activity of some 4-aminobenzamides.
AID129635Compound was evaluated for anticonvulsant activity against maximal electroshock induced seizures1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
Synthesis and anticonvulsant activity of analogues of 4-amino-N-(1-phenylethyl)benzamide.
AID112177Effective dose was evaluated for its anticonvulsant activity against subcutaneous induced metrazole convulsions in mice; activity value ranges from 38.83-46.001985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Anticonvulsant activity of some 4-aminobenzanilides.
AID140183Evaluated for toxicity by using rotarod test in mice at 4 hr; ++ indicates activity at 300 mg/kg.1984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
Anticonvulsant activity of some 4-aminobenzamides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (45.45)18.7374
1990's0 (0.00)18.2507
2000's1 (9.09)29.6817
2010's4 (36.36)24.3611
2020's1 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.50 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.06 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
phenytoin
[no description available]		2.6630imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
valproic acid
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.		2.3720branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
phenobarbital
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.		2.6630barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
ameltolide
ameltolide: structure given in first source; RN given refers to parent cpd		2.3720benzamides
4-aminobenzamide
[no description available]		1.9610benzamides
ConditionIndicatedRelationship StrengthStudiesTrials
Absence Seizure
[description not available]		02.6630
Seizures
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.		02.6630
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510